Compare AST SpaceMobile Inc (ASTS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AST SpaceMobile Inc vs TG Therapeutics Inc — how do they compare? AST SpaceMobile Inc trades at $74.3 (market cap $20.54B), while TG Therapeutics Inc trades at $49.58 (market cap $7.64B). The key difference: AST SpaceMobile Inc is far larger — about 2.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | TGTX | |
|---|---|---|
Market Cap | $20.54B | $7.64B |
Sector | Media | Health |
52-Week High | $133.09 | $59.06 |
52-Week Low | $36.91 | $26.94 |
Enterprise Value | $21.25B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AST SpaceMobile (ASTS) trades at $74.01, up 7.64% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with key resistance at $77. Fundamentally, revenue grew to $70.92M in 2025 but profitability remains challenged with a -573.67% net margin. The company is expanding its satellite network with SpaceX support and maintains a $1.2B-$1.3B backlog.
Outlook remains speculative with significant cash burn and execution risks, but potential exists if commercial service scales successfully. Analyst consensus targets $84.63 with mixed ratings. Key risks include sustained losses, capital intensity, and competitive pressure in the emerging satellite connectivity market.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
